In agreement with our previous studies on APO866, a prototype NAMPT inhibitor [19,36,38,39], we found that the new NAMPT inhibitors are highly toxic towards leukemia (AML and ALL), lymphoma (Burkitt) and multiple myeloma (MM) cells. The gene discussed is NAMPT; the disease is plasma cell myeloma.